Study #2026-0201
A Phase 1/2, Multicenter, Open-Label Study Of CIBI3003 In Participants With Relapsed Or Refractory Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
IBI3003
Description
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.